Charles Schwab
PRLD icon

Charles Schwab’s Prelude Therapeutics PRLD Stock Holding History

Charles Schwab’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-80,845
Closed -$65.4K – 3521
2025
Q2 		$65.4K Sell
80,845
-33,205
-29% -$28.8K ﹤0.01% 3437
2025
Q1 		$87.6K Sell
114,050
-3,150
-3% -$2.94K ﹤0.01% 3362
2024
Q4 		$149K Sell
117,200
-16,049
-12% -$21.3K ﹤0.01% 3359
2024
Q3 		$276K Buy
133,249
+5,216
+4% +$24.2K ﹤0.01% 3301
2024
Q2 		$488K Buy
128,033
+663
+0.5% +$2.7K ﹤0.01% 3205
2024
Q1 		$604K Buy
127,370
+2,670
+2% +$10.4K ﹤0.01% 2956
2023
Q4 		$532K Buy
124,700
+1,669
+1% +$5.08K ﹤0.01% 3059
2023
Q3 		$380K Buy
123,031
+37,238
+43% +$140K ﹤0.01% 3148
2023
Q2 		$386K Buy
85,793
+22,942
+37% +$137K ﹤0.01% 3165
2023
Q1 		$358K Sell
62,851
-870
-1% -$5.31K ﹤0.01% 3049
2022
Q4 		$385K Buy
63,721
+9,669
+18% +$62K ﹤0.01% 3062
2022
Q3 		$358K Sell
54,052
-9,148
-14% -$61.7K ﹤0.01% 3087
2022
Q2 		$330K Sell
63,200
-12,730
-17% -$64.8K ﹤0.01% 3178
2022
Q1 		$524K Sell
75,930
-9,207
-11% -$84.2K ﹤0.01% 3089
2021
Q4 		$1.06M Buy
85,137
+1,152
+1% +$18.7K ﹤0.01% 2888
2021
Q3 		$2.63M Buy
83,985
+11,362
+16% +$368K ﹤0.01% 2636
2021
Q2 		$2.08M Sell
72,623
-2,045
-3% -$72.8K ﹤0.01% 2706
2021
Q1 		$3.24M Buy
74,668
+6,100
+9% +$405K ﹤0.01% 2502
2020
Q4 		$4.91M Buy
+68,568
New +$3.41M ﹤0.01% 2230

Other funds holding PRLD

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Charles Schwab's PRLD Position: Q3 2025 in Review

Charles Schwab sold out of Prelude Therapeutics (PRLD) in Q3 2025, closing a stake of 80,845 shares — an estimated $65.4K sold.

Charles Schwab first reported a position in PRLD in Q4 2020 and held it in 19 quarters. The position peaked at $4.91M in Q4 2020. 47 funds tracked by Wall St. Rank hold PRLD as of Q3 2025.

  • Charles Schwab reported no remaining Prelude Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Charles Schwab sold 80,845 Prelude Therapeutics shares in Q3 2025, an estimated $65.4K.
  • Charles Schwab first reported a position in Prelude Therapeutics in Q4 2020 and held it in 19 quarters.
  • Charles Schwab's Prelude Therapeutics position peaked at $4.91M in Q4 2020.
  • 47 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q3 2025.

Based on Charles Schwab's 13F filing for Q3 2025, filed 10 Nov 2025.